Exostar offers cloud-based identity and access management and information security solutions, with its Secure Access Manager (SAM) providing federated identity, web single sign-on, and access controls. The company supports partner-centric research and digital health initiatives and also offers ProviderPass for compliant electronic prescribing of controlled substances. Exostar plans to enhance and expand its HIPAA-compliant solutions to help pharmaceutical companies, healthcare providers, and others collaborate securely and compliantly. Its life science and healthcare community has grown to over 1,000 global organizations that rely on SAM. Nearly 125,000 organizations leverage Exostar across industries, and the company emphasizes protecting sensitive data and intellectual property while reducing costs and improving productivity. Exostar offers cloud-based solutions that enable secure, cost-effective business-to-business collaboration, with its Secure Access Manager (SAM) authentication identity hub for the healthcare industry. SAM connects customers and organizations securely across large communities of users via a Software-as-a-Service model. The company announced a $5.0 million investment from the Merck Global Health Innovation Fund to accelerate growth and expansion of its healthcare and life sciences business and to move into related verticals. Exostar expanded from an Aerospace & Defense heritage into healthcare and life sciences and was originally established by some of the largest companies in the pharmaceutical and life sciences industry. Its life sciences identity hub includes more than 600 life science–focused companies and supports the collaboration initiatives of thousands of individuals. More broadly, Exostar supports over 100,000 companies in 150 countries and counts customers such as AstraZeneca, Boeing, Lockheed Martin, Merck, Raytheon, and Rolls-Royce among its community.

Total raised

$15M

Funding rounds

2

Latest round

Equity

Latest activity

Oct 2015